Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT051 in moderately to severely active ulcerative colitis
NCT05084261Phase 1Completed
- Sponsor
- Adiso Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of ADS051 in ulcerative colitis (UC) (4 arms), sponsored by Adiso Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at Day 58 and Change in Physical Exams, Labs, Vitals, ECG at Day 58. Started Nov 2021; status: completed.
02
Drugs
ADS051
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05084261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084261.